The
COVID-19 pandemic has resulted in excess deaths worldwide. Conventional
antiviral medicines have been used to relieve the symptoms, with limited
therapeutic effect. In contrast, Lianhua Qingwen
Capsule is reported to exert remarkable anti-COVID-19 effect. The current review aims to: 1) uncover the main pharmacological actions of Lianhua Qingwen
Capsule for managing
COVID-19; 2) verify the bioactive ingredients and pharmacological actions of Lianhua Qingwen
Capsule by network analysis; 3) investigate the compatibility effect of major botanical drug pairs in Lianhua Qingwen
Capsule; and 4) clarify the clinical evidence and safety of the combined
therapy of Lianhua Qingwen
Capsule and conventional drugs. Numerous bioactive ingredients in Lianhu Qingwen, such as
quercetin,
naringenin, β-
sitosterol,
luteolin, and
stigmasterol, were identified to target host
cytokines, and to regulate the immune defence in response to
COVID-19. Genes including
androgen receptor (AR),
myeloperoxidase (MPO),
epidermal growth factor receptor (EGFR),
insulin (INS), and
aryl hydrocarbon receptor (AHR) were found to be significantly involved in the pharmacological actions of Lianhua Qingwen
Capsule against
COVID-19. Four botanical drug pairs in Lianhua Qingwen
Capsule were shown to have synergistic effect for the treatment of
COVID-19. Clinical studies demonstrated the medicinal effect of the combined use of Lianhua Qingwen
Capsule and conventional drugs against
COVID-19. In conclusion, the four main pharmacological mechanisms of Lianhua Qingwen
Capsule for managing
COVID-19 are revealed.
Therapeutic effect has been noted against
COVID-19 in Lianhua Qingwen
Capsule.